Cloning Capsized?

Biopharmaceutical researchers fear how pending federal legislation outlawing the cloning of human cells will restrict their abilities to find cures for major degenerative diseases.1,2 Some also see lawmakers impinging on established nonhuman cloning techniques essential for the discovery of new drugs and therapies. The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) th

Written byTed Agres
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) that would ban the cloning of human cells for reproduction as well as for research. Of particular concern to scientists, the bill outlaws somatic cell nuclear transfer (SCNT) using human cells, a mechanism required in the new field of regenerative medicine. Potential uses for such therapeutic cloning include creating immune-compatible replacement tissue for diseased organs, such as the heart and pancreas, and treatments for neurodegenerative diseases, such as Parkinson's and Alzheimer's.

Scientists, ethicists, and politicians agree that human reproductive cloning should not be permitted. Therapeutic cloning is another matter, however. While most researchers in the field argue that human therapeutic cloning through SCNT will result in medical breakthroughs, some ethicists assert it must be banned because it will ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies